Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase ...
MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed ...
1d
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ...
Zacks Investment Research on MSN
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
NeoGenomics (NEO) shares soared 6.3% in the last trading session to close at $9.97. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...
The teclistamab-cqyv and daratumumab regimen achieved a 100% overall response rate and MRD negativity in newly diagnosed ...
A cancer treatment laboratory in Lewisville recently made a medical breakthrough that could greatly decrease the risk of the ...
(NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) ...
Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced the addition of a tissue-informed whole genome sequencing molecular residual ...
SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback